- Home
- CPBI vs NRXP Comparison
CPBI vs NRXP Comparison
Compare CPBI & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPBI | NRXP |
|---|---|---|
| Founded | 2023 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.3M | 70.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CPBI | NRXP |
|---|---|---|
| Price | $17.01 | $2.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.67 |
| AVG Volume (30 Days) | 4.4K | ★ 583.2K |
| Earning Date | 02-10-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.32 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $19,961,000.00 | $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $821.75 |
| P/E Ratio | $17.63 | ★ N/A |
| Revenue Growth | ★ 9.30 | N/A |
| 52 Week Low | $13.00 | $1.58 |
| 52 Week High | $17.14 | $6.01 |
Technical Indicators
Market Signals| Indicator | CPBI | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 63.30 | 45.80 |
| Support Level | $16.80 | $2.33 |
| Resistance Level | $17.03 | $2.48 |
| Average True Range (ATR) | 0.14 | 0.18 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 74.17 | 26.35 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.